好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cerebellar Volume Loss in Radiologically Isolated Syndrome
Multiple Sclerosis
P6 - Poster Session 6 (11:30 AM-1:00 PM)
9-014

Radiologically isolated syndrome (RIS) is often a pre-clinical form of multiple sclerosis (MS) detected incidentally when MRIs are obtained for reasons other than suspicion for MS. Volume loss in the cerebellum has been associated with motor and cognitive impairment in MS patients, most pronounced in patients with progressive disease. Whether cerebellar volume loss might be present in RIS prior to clinical symptoms of MS has not been investigated.

To compare volumes of posterior fossa structures in RIS subjects compared with healthy controls.

21 healthy individuals fulfilling 2009 criteria for RIS were retrospectively identified at the UCSF MS Center along with 38 age- and sex-matched healthy controls (HC). Subjects were scanned on a single 3T GE Signa scanner using a standardized protocol. White matter (WM) lesions were segmented on 3D T1-weighted images using a semiautomatic segmentation technique. Lesion-filled 3D T1-weighted images were segmented into gray matter (GM), WM and CSF using Statistical Parametric Mapping (SPM12) software. Cerebellar GM, WM and brainstem volumes were calculated on the lesion-filled 3D T1-weighted images using a customized version of Spatially Unbiased Infratentorial Toolbox version 3.2 in SPM12.

A general linear model adjusted for age and sex was used to assess the difference in normalized infratentorial structural volumes between RIS and HC. All statistical analyses were completed using SPSS (v. 19.0, Chicago, III). RIS subjects showed significant decreases in cerebellar WM (p = 0.003) and anterior cerebellar GM volumes (p = 0.005) compared to HC. Significant differences in posterior cerebellar GM (p = 0.134), total cerebellar GM and brainstem volumes (p = 0.172) between RIS and HC were not observed.

Cerebellar atrophy is present in RIS subjects. RIS has already been associated with atrophy in other areas of the brain, notably the thalamus. Further longitudinal studies may clarify the significance of these atrophy patterns.

Authors/Disclosures
Ilena George, MD
PRESENTER
The institution of Dr. George has received research support from Biogen.
No disclosure on file
Christina Azevedo, MD, FAAN (University of Southern California) Dr. Azevedo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi Genzyme. Dr. Azevedo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas Biopharma. Dr. Azevedo has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Azevedo has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Azevedo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Azevedo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. Azevedo has received research support from National Multiple Sclerosis Society. The institution of Dr. Azevedo has received research support from National Institutes of Health/National Institutes of Neurological Disorders and Stroke. The institution of Dr. Azevedo has received research support from National Multiple Sclerosis Society.
Christine Lebrun Frenay, MD, FAAN (CRCSEP Neurologie) Dr. Lebrun Frenay has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Revue Neurologique.
Orhun H. Kantarci, MD Dr. Kantarci has nothing to disclose.
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine) Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ali Raif Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanovel Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.
Darin T. Okuda, MD, FAAN (UT Southwestern Medical Center) Dr. Okuda has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Okuda has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cortechs AI. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Okuda has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RVL Pharmaceuticals, Inc.. Dr. Okuda has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Okuda has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Zenas BioPharma. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Okuda has received research support from Novartis. The institution of Dr. Okuda has received research support from EMD Serono. Dr. Okuda has received intellectual property interests from a discovery or technology relating to health care.
Daniel Pelletier, MD (Keck School of Medicine of USC) Dr. Pelletier has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Pelletier has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi Genzyme. Dr. Pelletier has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Pelletier has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Polpharma Biologics.
Matilde Inglese, MD, PhD (University of Genoa) Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI GENZYME. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK-SERONO. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MS Journal.